Table 3.
Comparison of parameters at the onset and at the follow up between Groups A and B.
| A (n = 30) GFR ≥ 90 | B (n = 24) GFR < 90 | p | |
|---|---|---|---|
| Age at the onset (years) | 12.69 ± 4.2 | 13.12 ± 2.93 | NS |
| Proteinuria at the onset (mg/kg/day) |
28 (0–967) | 15 (0–202) | NS |
| Creatinine at the onset (mg/dL) | 1.09 ± 0.5 | 0.95 ± 0.23 | NS |
| GFR at the onset (mL/min) | 62.95 ± 19.38 | 71.72 ± 12.77 | NS |
| IgA at the onset (mg/dL) | 252.74 ± 92.18 | 334.81 ± 120.35 | NS |
| C3 at the onset (mg/dL) | 112.43 ± 18.47 | 119.36 ± 19.71 | NS |
| C4 at the onset (mg/dL) | 25.99 ± 7.8 | 22.52 ± 8.29 | NS |
| Age at the follow-up (years) | 15.55 (8.85–19.35) | 17.48 (9.78–18.92) | NS |
| Proteinuria at the follow-up (mg/kg/day) | 4.15 (0–370) | 0 (0–73.3) | NS |
| Creatinine at the follow-up (mg/dL) | 0.64 ± 0.13 | 0.95 ± 0.25 | NS |
| GFR at the follow-up (mL/min) | 108.62 ± 16.19 | 73.92 ± 11.09 | NS |
| IgA at the follow-up (mg/dL) | 222.7 ± 112 | 304.65 ± 123.45 | NS |
| C3 at the follow-up (mg/dL) | 109.28 ± 19.94 | 113.61 ± 23.08 | NS |
| C4 at the follow-up (mg/dL) | 27.58 ± 26.72 | 22.06 ± 7.54 | NS |
R—renal protection; P—prednisone; I—immunosuppressive therapy; Aza—azathioprine; Ex—dexamethasone; Csa—cyclosporine; MMF—mycophenolate mofetil; GFR—glomerular filtration rate; NS—not significant.